THE EFFICACY OF SAMMA AND ITS LEADING DERIVATIVES AGAINST HIV-1
THE EFFICACY OF SAMMA AND ITS LEADING DERIVATIVES AGAINST HIV-1
批准号:
7605277
负责人:
MARLA J KELLER
金额:
$4.1万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-03-01 至 2008-02-29
关键词:
AcidsAgeAncillary StudyAntiviral AgentsBiological AssayClassComputer Retrieval of Information on Scientific Projects DatabaseCultured CellsDevelopmentEthersEthyl EtherEvaluationEventExhibitsFundingGenital systemGoalsGrantHIVHIV-1HumanInfectionInstitutionIrrigationLiquid substanceMenstrual cycleMononuclearMucous MembraneParentsPhasePhysiologicalResearchResearch PersonnelResourcesSAMMASexual TransmissionSimplexvirusSimulateSodium CompoundsSourceSystemUnited States National Institutes of HealthVaginaViralViral PhysiologyWeekantimicrobial drugbasecohortcytotoxicitymicrobicidenovelpathogenprogramsrectaltissue culture
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
The overall goal of this program project is to develop safe and effective topical antimicrobial agents for vaginal or rectal use that will block sexual transmission of human immunodeficiency virus (HIV) and other sexually transmitted pathogens including herpes simplex virus (HSV). The overall program project focuses on the development of a novel class of candidate compounds based on the parent compound, sodium dimandelic acid ether (SAMMA). SAMMA has excellent anti-HIV and HSV activity, while exhibiting no cytotoxicity in tissue culture. Project 3 of the Program focuses on determining the efficacy of SAMMA and its derivatives in biologically relevant culture systems. While mononuclear cell cultures may provide important information for the evaluation of microbicides, anatomical, physiological and immunological issues suggest they may not adequately simulate events that occur in human genital tract fluids and mucosal tissues. In preliminary studies, we have demonstrated that cervicovaginal lavage fluid (CVL) has intrinsic antiviral activity against HSV, and to a lesser extent, HIV. The goal of this ancillary study is to further characterize the anti-viral activity of CVL. It is important to control for factors such as age, menstrual cycle and intercurrent infections. Therefore, we propose to obtain CVL from a cohort of 20 subjects who will be assessed twice (2-weeks apart). The anti-viral (HSV and HIV) activity in the CVL will be assayed and correlated with age, phase of menstrual cycle, and presence of intercurrent infections. In addition, studies to define the mechanism of anti-HSV activity will be conducted. The stability of SAMMA, leading derivatives and other candidate topical compounds in the presence of CVL will also be assessed. Defining the antiviral activity present in genital tract fluids and their impact on microbicide activity is critical in the development of candidate microbicides.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Einstein-Montefiore Clinical and Translational Science Award Hub
-
批准号:10622099
-
项目类别:
-
资助金额:$436.8万
-
财政年份:2023
-
负责人:MARLA J KELLER
-
依托单位:
Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV-2 Plasma to Placebo in COVID-19 hospitalized pa
-
批准号:10166008
-
项目类别:
-
资助金额:$432.52万
-
财政年份:2020
-
负责人:MARLA J KELLER
-
依托单位:
CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patients
-
批准号:10158737
-
项目类别:
-
资助金额:$100.34万
-
财政年份:2020
-
负责人:MARLA J KELLER
-
依托单位:
Clinical and Translational Science Award
-
批准号:10112978
-
项目类别:
-
资助金额:$427.42万
-
财政年份:2018
-
负责人:MARLA J KELLER
-
依托单位:
Clinical and Translational Science Award
-
批准号:9886296
-
项目类别:
-
资助金额:$427.42万
-
财政年份:2018
-
负责人:MARLA J KELLER
-
依托单位:
Clinical and Translational Science Award
-
批准号:10357784
-
项目类别:
-
资助金额:$427.42万
-
财政年份:2018
-
负责人:MARLA J KELLER
-
依托单位:
Modifies of PrEP Efficacy in US & African Women: Age, Hormones, Sex & Microbiota
-
批准号:8448509
-
项目类别:
-
资助金额:$89.57万
-
财政年份:2013
-
负责人:MARLA J KELLER
-
依托单位:
Safety of Non-Medicated Intravaginal Rings for Microbicide Delivery
-
批准号:8012508
-
项目类别:
-
资助金额:$12.45万
-
财政年份:2010
-
负责人:MARLA J KELLER
-
依托单位:
Clinical Study to Measure Pharmacokinetics, Pharmacodynamics and Safety of a TDF
-
批准号:8210597
-
项目类别:
-
资助金额:$46.11万
-
财政年份:2009
-
负责人:MARLA J KELLER
-
依托单位:
EFFECTS OF HORMONES ON MUCOSAL IMMUNE MEDIATORS ACROSS THE MENSTRUAL CYCLE
-
批准号:7718170
-
项目类别:
-
资助金额:$17.93万
-
财政年份:2008
-
负责人:MARLA J KELLER
-
依托单位:
EFFECTS OF HORMONES ON MUCOSAL IMMUNE MEDIATORS ACROSS THE MENSTRUAL CYCLE
-
批准号:7605356
-
项目类别:
-
资助金额:$3.4万
-
财政年份:2007
-
负责人:MARLA J KELLER
-
依托单位:
EFFECTS OF HIV ON BONE MASS IN THE ELDERLY
-
批准号:7380524
-
项目类别:
-
资助金额:$4.59万
-
财政年份:2006
-
负责人:MARLA J KELLER
-
依托单位:
EFFECT OF REPEATED APPLICATIONS OF PRO 2000/5 GEL (P) ON INFLAMMATORY MEDIATORS
-
批准号:7380538
-
项目类别:
-
资助金额:$2.69万
-
财政年份:2006
-
负责人:MARLA J KELLER
-
依托单位:
MULTITARGETED MICROBICIDE COMBINATIONS TO BLOCK HIV
-
批准号:7380518
-
项目类别:
-
资助金额:$5.38万
-
财政年份:2006
-
负责人:MARLA J KELLER
-
依托单位:
TO EVALUATE THE EFFICACY OF SAMMA AND ITS LEADING DERIVATIVES AGAINST HIV-1
-
批准号:7380526
-
项目类别:
-
资助金额:$4.9万
-
财政年份:2006
-
负责人:MARLA J KELLER
-
依托单位:
Microbicide Effects on Efficacy, Safety, Innate Immunity
-
批准号:7572920
-
项目类别:
-
资助金额:$44.23万
-
财政年份:2005
-
负责人:MARLA J KELLER
-
依托单位:
Microbicide Effects on Efficacy, Safety, Innate Immunity
-
批准号:7531462
-
项目类别:
-
资助金额:$20.01万
-
财政年份:2005
-
负责人:MARLA J KELLER
-
依托单位:
Microbicide Effects on Efficacy, Safety, Innate Immunity
-
批准号:7221949
-
项目类别:
-
资助金额:$20.74万
-
财政年份:2005
-
负责人:MARLA J KELLER
-
依托单位:
EFFECT OF REPEATED APPLICATIONS OF PRO 2000/5 GEL (P) ON INFLAMMATORY MEDIATO
-
批准号:7202511
-
项目类别:
-
资助金额:$11.22万
-
财政年份:2005
-
负责人:MARLA J KELLER
-
依托单位:
MULTITARGETED MICROBICIDE COMBINATIONS TO BLOCK HIV
-
批准号:7202486
-
项目类别:
-
资助金额:$7.16万
-
财政年份:2005
-
负责人:MARLA J KELLER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: